

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, and comprises a heavy chain variable region sequence at least [[85%]] 75% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least [[85%]] 75% identical to the amino acid sequence of SEQ ID NO:3.
2. (Previously Presented) The antibody or functional fragment of claim 1, wherein said antibody or functional fragment inhibits cell proliferation of CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), or COLO-206F (DSMZ Accession No. ACC 21) cells.
3. (Cancelled)
4. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment induces apoptosis of at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.
- 5.-6. (Cancelled).
7. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence that is at least [[90%]] 80% identical to the amino acid sequence of SEQ ID NO:1.
8. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a light chain variable region sequence that is at least [[90%]] 80% identical to the amino acid sequence of SEQ ID NO:3.
9. (Currently Amended) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:3 and ~~specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ~~

Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

10. (Cancelled)

11. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises the heavy chain and light chain variable region amino acid sequence of SEQ ID NOS:1 and 3 and specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

12. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment is a human antibody.

13. (Previously Presented) The purified antibody of claim 1, wherein said antibody is a monoclonal antibody.

14. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells is selected from the group consisting of F_V, Fab, Fab', and F(ab')₂.

15. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells comprises a fragment that is at least 90% identical to the sequence of SEQ ID NO:1 or SEQ ID NO:3.

16. (Previously Presented) The purified antibody or functional fragment of claim 1, wherein said functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144),

COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells comprises a fragment of the sequence of SEQ ID NO:1 or SEQ ID NO:3.

17.-53. (Canceled)

54. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least [[95%]] 85% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least at least [[90%]] 80% identical to the amino acid sequence of SEQ ID NO:3.

55. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least [[90%]] 80% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least at least [[95%]] 85% identical to the amino acid sequence of SEQ ID NO:3.

56. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

57. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a heavy chain variable region sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:1.

58. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a light chain variable region sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:3.

59. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a heavy chain variable region sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:1.

60. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a light chain variable region sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:3.

61. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a heavy chain variable region sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:1.

62. (Currently Amended) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a light chain variable region sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:3.

63. (Currently Amended) A purified antibody, or a functional fragment thereof that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein the antibody comprises a heavy chain variable region at least 75% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region at least 75% identical to the amino acid sequence of SEQ ID NO:3 with a conservative amino acid substitution in either SEQ ID NO:1 or SEQ ID NO:3.

64. (Previously Presented) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:1.

65. (Previously Presented) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:3.

66. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3.

67. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

68. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

69. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

70. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3.

71. (New) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, and comprises a heavy chain variable region sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 75% identical to the amino acid sequence of SEQ ID NO:3, and wherein the heavy or light chain variable region sequence has an insertion or deletion of one amino acid residue.

72. (New) The purified antibody or functional fragment of claim 71, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 80% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 80% identical to the amino acid sequence of SEQ ID NO:3.

73. (New) The purified antibody or functional fragment of claim 71, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3.

74. (New) The purified antibody or functional fragment of claim 71, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

75. (New) The purified antibody or functional fragment of claim 71, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 95%

identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3.

76. (New) The purified antibody or functional fragment of claim 1, wherein the heavy or light chain variable region sequence has an insertion or deletion of one amino acid residue.

77. (New) The purified antibody or functional fragment of claim 71, wherein the heavy or light chain variable region sequence has an insertion or deletion of one amino acid residue.

78. (New) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:3, and wherein said antibody, or functional fragment thereof has a one amino acid insertion or deletion in either or both of SEQ ID NO:1 and SEQ ID NO:3.